RAPT Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, RAPT Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
RAPT Therapeutics: 8 sponsored US clinical trials, 1 recruiting.
RAPT Therapeutics sponsors 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ig-E Mediated Food Allergy, with 1 trials.
Upper-quartile sponsor footprint
RAPT Therapeutics sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
NCT07220811
Study of RPT193 in Healthy Adult Male Subjects
NCT06087978
Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma
NCT05935332
An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis
NCT05399368
FLX475 in Combination With Ipilimumab in Advanced Melanoma
NCT04894994
A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis
NCT04271514
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab
NCT03674567
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
NCT02335814
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 4 |
Therapeutic Areas
What is open in the RAPT Therapeutics pipeline
1 recruiting of 8 indexed (13% open); 3 completed (38%).
Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).
Top condition: Ig-E Mediated Food Allergy (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
RAPT Therapeutics: open-pipeline peers nationwide
Peers matched on 8 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
RAPT Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 13% open enrollment (± trial volume)
- Addario Lung Cancer Medical Institute · 13% recruiting · 8 trials
- American University · 13% recruiting · 16 trials
- Annexon · 13% recruiting · 8 trials
- Ansun Biopharma · 13% recruiting · 8 trials
Related
What to do with this RAPT Therapeutics page
8 registered trials is a research-attention snapshot, not an endorsement of RAPT Therapeutics or any single study.
- 1 of RAPT Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Ig-E Mediated Food Allergy is the condition RAPT Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ig-E Mediated Food Allergy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
RAPT Therapeutics pipeline card: 8 registered trials from official public datasets.Report a data error.